Building Small Molecule Drugs that Are Superior to Biologics

Building Small Molecule Drugs that Are Superior to Biologics

Though structure-based drug discovery has been long been used, technologic advances have given this approach greater power. ShouTi believes its next-generation, computational, structure-based drug discovery platform will allow it to develop small molecule drugs that are superior in safety and efficacy to biologic and peptide therapies its seeking to replace. We spoke to Raymond Stevens, CEO of ShouTi, about the company’s structure-based drug discovery platform, how it works, and why he believes it will be able to produce small molecule drugs that will be superior to biologics.?


要查看或添加评论,请登录

Daniel Levine的更多文章

社区洞察

其他会员也浏览了